What metastatic pancreatic cancer reveals about patient choice, real-world evidence and the denominator Two contemporary datasets appear to describe radically different treatment uptake in metastatic pancreatic cancer: 72% untreated in …

What Spain’s new HTA system means for biotech reimbursement after European Joint Clinical Assessment Europe has harmonised part of the clinical assessment. It has not harmonised reimbursement. Spain’s Real Decreto …

For a small biotech, the most expensive word in European market access is often not “no”. It is “later”. Belgium’s new Early and Equitable Fast Access (EEFA) pathway aims to …

France has not launched a new early-access scheme. It has changed the operating rules of an established route that can place innovative medicines into funded clinical use before conventional reimbursement …

Why Britain’s subscription model is trying to make antimicrobial stewardship compatible with pharmaceutical innovatio There is something economically strange about a good antibiotic. We want it to exist. We may …

A practical, evidence-led guide to DiGA, G-BA methods assessment, §137e evidence generation, hospital NUB funding, §137h high-risk device assessment and the emerging problem of undocumented AI inside “usual care”. Editorial …